1982-P: Glucagon-Like Peptide-2 Inhibits Postprandial Gallbladder Emptying in Healthy Male Individuals—A Randomized, Double-Blinded, Placebo-Controlled Study

Diabetes ◽  
2019 ◽  
Vol 68 (Supplement 1) ◽  
pp. 1982-P
Author(s):  
NINA L. HANSEN ◽  
CHRISTINA CHARLOTTE NEXØE-LARSEN ◽  
ANDREAS BRØNDEN ◽  
ALEXANDER S. CHRISTENSEN ◽  
DAVID P. SONNE ◽  
...  
Keyword(s):  
Controlled Study ◽  
Gallbladder Emptying ◽  
Healthy Male ◽  
Glucagon Like Peptide ◽  
Double Blinded

scholarly journals Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study

2020 ◽  
Vol 11 (12) ◽  
pp. e00257
Author(s):  
Nina L. Hansen ◽  
Andreas Brønden ◽  
Christina C. Nexøe-Larsen ◽  
Alexander S. Christensen ◽  
David P. Sonne ◽  
...  
Keyword(s):  
Crossover Study ◽  
Gallbladder Emptying ◽  
Glucagon Like Peptide ◽  
Double Blinded

884: Phase I, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Investigate the Safety, Tolerability, and Pharmacokinetics of DA-8159

2004 ◽  
Vol 171 (4S) ◽  
pp. 234-234 ◽  
Author(s):  
Harin Padma-Nathan ◽  
Jae Seung Pacik ◽  
Byoung Ok Ahn ◽  
Kyung Koo Kang ◽  
Mi Young Bahng ◽  
...  
Keyword(s):  
Phase I ◽  
Controlled Study ◽  
Healthy Male ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Male Subjects

Oral Alpha Lipoic Acid Treatment for Symptomatic Diabetic Peripheral Neuropathy: A Randomized Double-Blinded Placebo-Controlled Study

2020 ◽  
Vol 20 (9) ◽  
pp. 1531-1534 ◽  
Author(s):  
Mamdouh R. El-Nahas ◽  
Ghada Elkannishy ◽  
Hala Abdelhafez ◽  
Enas T. Elkhamisy ◽  
Amr A. El-Sehrawy
Keyword(s):  
Peripheral Neuropathy ◽  
Lipoic Acid ◽  
Diabetic Peripheral Neuropathy ◽  
Study Groups ◽  
Controlled Study ◽  
Alpha Lipoic Acid ◽  
Disability Score ◽  
Perception Threshold ◽  
Outcome Parameters ◽  
Double Blinded

Background: Alpha-lipoic acid (ALA) was used in the treatment of diabetic peripheral neuropathy (DPN) using different routes, doses and treatment durations. The aim of this work is to assess the efficacy of oral 600mg ALA twice daily over 6 months in the treatment of patients with DPN. Methods: This is a prospective, single-center, double-blinded, placebo-controlled study conducted at the outpatient clinic of Mansoura Specialized Hospital, Mansoura University. A total of 200 patients with DPN were randomly assigned to add on treatment with either oral 600mg twice daily ALA (n=100) or placebo (n=100) for 6 months. Treatment outcome was assessed using vibration perception threshold (VPT), neurological symptom score (NSS), neurological disability score (NDS), and visual analog scale (VAS) for pain at baseline and at each visit (1, 3 and 6 months) after the start of treatment. Results: Comparison between the study groups regarding the baseline data revealed no statistically significant differences. with respect to the outcome parameters, no significant differences were found between the studied groups at baseline. However, in subsequent visits, ALA-treated patients had significantly better results regarding almost all the outcome parameters (NSS, NDS, VAS, VPT). Mild nausea was reported in 6 patients. None of the studied patients discontinued treatment. Conclusions: Oral 600mg ALA twice-daily treatment for DPN over 6 months is effective, safe and tolerable.

Botulinum toxin improves forehead scars after Mohs surgery: a randomized, double-blinded, controlled study

2021 ◽  
Author(s):  
Matthew J. Lin ◽  
Daniel M. Bernstein ◽  
Richard L. Torbeck ◽  
Danielle P. Dubin ◽  
Joshua D. Rosenberg ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Controlled Study ◽  
Mohs Surgery ◽  
Double Blinded

Effects of PYY3–36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men

2014 ◽  
Vol 306 (11) ◽  
pp. E1248-E1256 ◽  
Author(s):  
Julie Berg Schmidt ◽  
Nikolaj Ture Gregersen ◽  
Sue D. Pedersen ◽  
Johanne L. Arentoft ◽  
Christian Ritz ◽  
...  
Keyword(s):  
Energy Expenditure ◽  
Synergistic Effect ◽  
Energy Intake ◽  
Fat Metabolism ◽  
Vital Signs ◽  
Healthy Male ◽  
Double Blinded ◽  
Male Subjects ◽  
Infusion Period ◽  
Blood Variables

Our aim was to examine the effects of GLP-1 and PYY3–36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and fat metabolism, ghrelin, and vital signs in healthy overweight men. Twenty-five healthy male subjects participated in this randomized, double-blinded, placebo-controlled, four-arm crossover study (BMI 29 ± 3 kg/m2, age 33 ± 9 yr). On separate days they received a 150-min intravenous infusion of 1) 0.8 pmol·kg−1·min−1 PYY3–36, 2) 1.0 pmol·kg−1·min−1 GLP-1, 3) GLP-1 + PYY3–36, or 4) placebo. Ad libitum energy intake was assessed during the final 30 min. Measurements of appetite sensations, energy expenditure and fat oxidation, vital signs, and blood variables were collected throughout the infusion period. No effect on energy intake was found after monoinfusions of PYY3–36 (−4.2 ± 4.8%, P = 0.8) or GLP-1 (−3.0 ± 4.5%, P = 0.9). However, the coinfusion reduced energy intake compared with placebo (−30.4 ± 6.5%, P < 0.0001) and more than the sum of the monoinfusions ( P < 0.001), demonstrating a synergistic effect. Coinfusion slightly increased sensation of nausea ( P < 0.05), but this effect could not explain the effect on energy intake. A decrease in plasma ghrelin was found after all treatments compared with placebo (all P < 0.05); however, infusions of GLP-1 + PYY3–36 resulted in an additional decrease compared with the monoinfusions (both P < 0.01). We conclude that coinfusion of GLP-1 and PYY3–36 exerted a synergistic effect on energy intake. The satiating effect of the meal was enhanced by GLP-1 and PYY3–36 in combination compared with placebo. Coinfusion was accompanied by slightly increased nausea and a decrease in plasma ghrelin, but neither of these factors could explain the reduction in energy intake.

Sign in / Sign up

Export Citation Format

Share Document